![Eamonn Connolly](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Eamonn Connolly worked as the Head of the Research Department at BioGaia AB from 2010 to 2011.
He then served as the Chief Scientific Officer at Infant Bacterial Therapeutics AB from 2013 to 2021.
Dr. Connolly obtained an undergraduate degree from The University of Manchester and a doctorate degree from the University of Manchester Institute of Science & Technology.
Eerdere bekende functies van Eamonn Connolly
| Bedrijven | Functie | Einde |
|---|---|---|
| INFANT BACTERIAL THERAPEUTICS AB | Hoofd Techniek/Wetenschap/O&O | 01-01-2021 |
| BIOGAIA AB | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Eamonn Connolly
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
12
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
BioGaia AB
 BioGaia AB Pharmaceuticals: OtherHealth Technology Develops health care products such as foods with healthy additives and provides pharmaceutical research services | Health Technology |
The University of Manchester
 The University of Manchester Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Manchester Institute of Science & Technology
 University of Manchester Institute of Science & Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Infant Bacterial Therapeutics AB
 Infant Bacterial Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of gastroschisis | Health Technology |
Kies MarketScreener 
